PMI

Picard Medical, Inc.

Picard Medical, Inc. (PMI) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Profitability (C). The rating has held at C+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
B-
Factor Score 3.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.6
EV / EBITDA -1.2
Rev Growth YoY 38.6%
Gross Margin 18.6%
Price Return 3M 105.4%
Price Return 12M -94.7%
Catalyst Signal 0.00
Market Cap $17.8M
TTM Revenue $6.3M
Price / Sales 2.8
ROE N/A

Historical Factor Score Progression

Held C+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (3.0) C+ (2.6) C (2.3) B- (3.1) C+ (2.6) C+ (2.7)
2026-11-07 B- (3.0) C+ (2.7) C (2.3) C+ (2.7) C+ (2.7) C+ (2.7)
2026-10-31 B- (3.0) C+ (2.7) C (2.3) C- (1.9) C+ (2.7) C+ (2.5)
2026-10-24 B- (3.0) C+ (2.7) C (2.3) C- (1.9) C+ (2.6) C (2.5)
2026-10-17 B- (3.0) C+ (2.7) C (2.3) C- (1.9) C+ (2.6) C (2.5)
Page 1 of 3